Overview of R/R MM and Current Treatment Options for Patients with Relapse
Therapeutic Strategies After Relapse for Patients With Heavily Pretreated Disease
Promising New Treatment Options for Patients With R/R MM
Putting It All Together: Key Points for Pharmacists
Sagar Lonial, MD
Professor and Chair
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute of Emory University
Kathryn Maples, PharmD, BCOP
Clinical Pharmacy Specialist, Multiple Myeloma
Department of Pharmacy
Winship Cancer Institute
The goal of this activity is to educate oncology pharmacists and other healthcare professionals about the recent improvements in the care of R/R MM and applying those improvements to their patients.
This educational program is intended for oncology pharmacists and other healthcare providers who care for patients with relapsed/refractory multiple myeloma.
Upon completion of this activity, participants should be able to:
- Describe the efficacy and safety evidence of novel combination therapeutic regimens for R/R MM
- Delineate the dose, schedule of administration, and dose modifications for newer classes of agents indicated emerging for R/R MM
- Counsel patients with heavily pretreated MM about potential risks and drug-drug interactions when starting new therapies based on comorbidities, comedications, and previous therapies
- Refer to current resources for management of toxicities with newer agents and combination regimens in patients with heavily pretreated R/R MM
- Evaluate ongoing major clinical trials investigating novel therapeutic approaches in R/R MM
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education. UAN:JA4008176-0000-21-071-L01-P
Type of Activity: Knowledge
Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.